title: Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis.
abstract: OBJECTIVE
  The risk of anemia due to bevacizumab-based chemotherapy has not been well described, and new randomized controlled trials (RCTs) have been reported in recent years. We therefore conducted an up-to-date meta-analysis of RCTs to fully characterize the risk of anemia with bevacizumab.
  
  
  METHODS
  We carried out an electronic search of Medline, Embase, and The Cochrane Central Register of Controlled Trials to investigate the effects of RCTs on bevacizumab treatment on cancer patients up to October 2014, and random or fixed-effect meta-analytical models were used to assess the risk ratio (RR) of anemia due to the use of bevacizumab according to the heterogeneity of included studies.
  
  
  RESULTS
  A total of 13,173 patients were included in this analysis from 18 RCTs. Among those patients receiving bevacizumab and chemotherapy, the incidences of all-grade and high-grade (grade 3 and above) anemia were 24% (95% confidence interval (CI) 13-41%) and 4.0% (95% CI 3.0-6.0%), respectively. Bevacizumab-containing therapy did not significantly decreased the risk of developing all-grade anemia (RR 0.872, 95% CI 0.739-1.029, P = 0.104) and high-grade anemia (RR 0.850, 95% CI 0.720-1.002, P = 0.053), which is not in agreement with previous meta-analysis. On subgroup analysis, we did not find significant risk differences based on bevacizumab dosage, tumor types, and concomitant drugs. When stratified by dose level, a significantly decreased risk of high-grade anemia with bevacizumab was obtained in a lower dose level (2.5 mg/kg/week, RR 0.773, 95% CI 0.611-0.978, P = 0.031) compared to control group.
  
  
  CONCLUSIONS
  Bevacizumab did not significantly reduce the risk of anemia with chemotherapy in cancer patients.
authors.affiliation: Cardiothoracic Surgery, Huaihe Hospital, Henan University, No. 8 Baobei Road, Kaifeng, 475000, Henan, China.
authors.forename: Zuo-Pei
authors.initials: ZP
authors.lastname: Wang
authors.forename: Hai-Feng
authors.initials: HF
authors.lastname: Zhang
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.forename: Bao-Li
authors.initials: BL
authors.lastname: Hu
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Wei
authors.forename: Yong-Yuan
authors.initials: YY
authors.lastname: Guo
mesh_terms: D000740:Anemia / Q000453:epidemiology* / Q000209:etiology; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D009369:Neoplasms / Q000188:drug therapy; D012306:Risk
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
references.citation: J Clin Oncol. 2005 Feb 1;23(4):792-9
references.pmid: 15681523
references.citation: Drug Discov Today. 2013 Sep;18(17-18):872-9
references.pmid: 23688584
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3239-47
references.pmid: 20498403
references.citation: BioDrugs. 2008;22(2):113-20
references.pmid: 18345708
references.citation: Acta Oncol. 2011 Oct;50(7):997-1005
references.pmid: 21554028
references.citation: Chin J Cancer. 2011 Oct;30(10 ):682-9
references.pmid: 21959045
references.citation: Oncologist. 2007 Jun;12(6):713-8
references.pmid: 17602060
references.citation: Cancer. 2013 Jan 15;119(2):339-47
references.pmid: 22811009
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4743-50
references.pmid: 17909199
references.citation: J Clin Oncol. 2012 May 1;30(13):1534-40
references.pmid: 22454414
references.citation: Nat Med. 2006 Jul;12(7):793-800
references.pmid: 16799557
references.citation: J Clin Oncol. 2010 May 1;28(13):2137-43
references.pmid: 20368558
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references.pmid: 19720927
references.citation: Cancer Invest. 2009 Oct;27(8):851-6
references.pmid: 19603304
references.citation: N Engl J Med. 2011 Dec 29;365(26):2473-83
references.pmid: 22204724
references.citation: N Engl J Med. 2007 Dec 27;357(26):2666-76
references.pmid: 18160686
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18513-8
references.pmid: 19017793
references.citation: Nat Rev Drug Discov. 2004 May;3(5):391-400
references.pmid: 15136787
references.citation: Lancet. 2007 Dec 22;370(9605):2103-11
references.pmid: 18156031
references.citation: J Angiogenes Res. 2009 Dec 23;1:9
references.pmid: 20076778
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3617-22
references.pmid: 20606091
references.citation: J Clin Oncol. 2012 Jul 10;30(20):2509-15
references.pmid: 22665541
references.citation: J Clin Oncol. 2011 Oct 20;29(30):3968-76
references.pmid: 21844504
references.citation: N Engl J Med. 2012 Jan 26;366(4):299-309
references.pmid: 22276820
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1227-34
references.pmid: 19188680
references.citation: Oncologist. 2007 Mar;12(3):356-61
references.pmid: 17405901
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: J Clin Oncol. 2009 May 1;27(13):2231-7
references.pmid: 19307500
references.citation: Eur J Clin Pharmacol. 2014 Aug;70(8):893-906
references.pmid: 24858820
references.citation: Lancet Oncol. 2013 Sep;14(10):933-42
references.pmid: 23932548
references.citation: Lung Cancer. 2012 Jun;76(3):362-7
references.pmid: 22244743
references.citation: Eur J Cancer. 2011 May;47(8):1161-74
references.pmid: 21470847
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: J Clin Oncol. 2010 May 1;28(13):2280-5
references.pmid: 20351323